Standard chemotherapy for breast cancer, regardless of ER/PR.HER2 status damages the ovaries, causing temporary or permanent chemotherapy-related amenorrhea (CRA) in many women who survive cancer [118]. This evidence concerns the gene ERBB2 and breast carcinoma.